As of today (2024-05-24), the Forward Annual Dividend Yield of Sierra Oncology is 0.00%.
As of today (2024-05-24), the Trailing Annual Dividend Yield of Sierra Oncology is 0.00%.
SRRA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Sierra Oncology's Forward Dividend Yield %
For the Biotechnology subindustry, Sierra Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sierra Oncology's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sierra Oncology's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's Forward Dividend Yield % falls into.
Sierra Oncology Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Sierra Oncology (NAS:SRRA) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Sierra Oncology Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Sierra Oncology's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sierra Oncology (Sierra Oncology) Business Description
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRA has been successfully added to your